Design, Synthesis and Molecular Docking Studies of Pyrazoline Derivatives as PI3K Inhibitors


Cite item

Full Text

Abstract

Aim:Design, synthesis and molecular docking studies of quinoline/naphthalene containing pyrazoline derivatives as PI3K inhibitors.

Background:Phosphatidylinositol 3-kinases (PI3Ks) belong to the family of enzymes, which are associated with various cellular functions such as cell growth, proliferation, differentiation etc. Overexpression or any changes in these functions may result in various abnormalities, which in turn cause cancer.

Objectives:To perform synthesis and molecular docking studies of quinoline/naphthalene containing pyrazoline derivatives as PI3K inhibitors.

Methods:2-Chloroquinoline-3-carbaldehyde was synthesized by a reaction of acetanilide and POCl3. The latter was reacted with substituted acetophenones to synthesize chalcones, which were reacted with substituted phenyl hydrazines to yield pyrazoline derivatives (Series I). Similarly, pchloro benzaldehyde was reacted with 2-acetonapthone to yield chalcone with substituted phenyl hydrazines to yield pyrazoline derivatives (Series II).

Results:The synthetic compounds were subjected to molecular modelling experiments using Schrodinger 2016 software and evaluated in silico for their PI3K binding affinities. All the compounds had better docking scores than AMG-319 (-4.36 Kcal/mol) and comparable docking scores with PI-103 (-6.83 Kcal/mol).

Conclusion:Compounds 5 and 3 had the best docking scores (-7.85 and -7.17 Kcal/mol, respectively). The synthesized compounds have better docking scores than the reference drug AMG-319. As a result, they might be used as lead molecules in investigating PI3K inhibitors.

About the authors

Rohit Kumar

Department of Pharmaceutical Sciences and Natural Products,, Central University of Punjab

Email: info@benthamscience.net

Arvind Kumar

Department of Pharmaceutical Sciences and Natural Products,, Central University of Punjab

Email: info@benthamscience.net

Adarsh Kumar

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab

Email: info@benthamscience.net

Ankit Singh

Department of Pharmaceutical Sciences and Natural Product, Central University of Punjab

Email: info@benthamscience.net

Pradeep Kumar

Department of Pharmaceutical Sciences and Natural Products, Central University of Punjab

Author for correspondence.
Email: info@benthamscience.net

References

  1. Nagai, H.; Kim, Y.H. Cancer prevention from the perspective of global cancer burden patterns. J. Thorac. Dis., 2017, 9(3), 448-451.
  2. Kuszyk, B.S.; Corl, F.M.; Franano, F.N.; Bluemke, D.A.; Hofmann, L.V.; Fortman, B.J.; Fishman, E.K. Tumor transport physiology: Implications for imaging and imaging-guided therapy. AJR Am. J. Roentgenol., 2001, 177(4), 747-753. doi: 10.2214/ajr.177.4.1770747 PMID: 11566666
  3. Rosielle, D.A.; Atwood, M.; Marks, S.; Rilling, W.S. Palliative care and symptom management, Interventional oncology: Principles and practice of image-guided. 2016, 294-314.
  4. Laird, P.W. Cancer epigenetics. Hum. Mol. Genet., 2005, 14(S1), R65-R76. doi: 10.1093/hmg/ddi113 PMID: 15809275
  5. Chaffer, C.L.; Weinberg, R.A. A perspective on cancer cell metastasis. Science, 2011, 331, 1559-1564. doi: 10.1126/science.1203543 PMID: 21436443
  6. Lu, P.; Weaver, V.M.; Werb, Z. The extracellular matrix: A dynamic niche in cancer progression. J. Cell Biol., 2012, 196(4), 395-406. doi: 10.1083/jcb.201102147 PMID: 22351925
  7. Hejmadi, M. Introduction to cancer biology; Bookboon, 2014, pp. 1-48.
  8. Akinleye, A.; Avvaru, P.; Furqan, M.; Song, Y.; Liu, D. Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics. J. Hematol. Oncol., 2013, 6(1), 88. doi: 10.1186/1756-8722-6-88 PMID: 24261963
  9. Kong, D.; Yamori, T. Phosphatidylinositol 3-kinase inhibitors: Promising drug candidates for cancer therapy. Cancer Sci., 2008, 99(9), 1734-1740. doi: 10.1111/j.1349-7006.2008.00891.x PMID: 18616528
  10. Aly, R.M.; Serya, R.; Amira, M.; Al-Ansary, G.H.; Abou El Ella, D.A. Quinoline-based small molecules as effective protein kinases inhibitors. J. Am. Sci., 2016, 12, 10-32.
  11. Jain, S.; Chandra, V.; Kumar Jain, P.; Pathak, K.; Pathak, D.; Vaidya, A. Comprehensive review on current developments of quinoline-based anticancer agents. Arab. J. Chem., 2019, 12(8), 4920-4946. doi: 10.1016/j.arabjc.2016.10.009
  12. Qian, Y.; Zhang, H.J.; Zhang, H.; Xu, C.; Zhao, J.; Zhu, H.L. Synthesis, molecular modeling, and biological evaluation of cinnamic acid metronidazole ester derivatives as novel anticancer agents. Bioorg. Med. Chem., 2010, 18(14), 4991-4996. doi: 10.1016/j.bmc.2010.06.003 PMID: 20594859
  13. Wang, H.H.; Qiu, K.M.; Cui, H.E.; Yang, Y.S. Yin-Luo; Xing, M.; Qiu, X.Y.; Bai, L.F.; Zhu, H.L. Synthesis, molecular docking and evaluation of thiazolyl-pyrazoline derivatives containing benzodioxole as potential anticancer agents. Bioorg. Med. Chem., 2013, 21(2), 448-455. doi: 10.1016/j.bmc.2012.11.020 PMID: 23245802
  14. Shahavar Sulthana, S.; Arul Antony, S.; Balachandran, C.; Syed Shafi, S. Thiophene and benzodioxole appended thiazolyl-pyrazoline compounds: Microwave assisted synthesis, antimicrobial and molecular docking studies. Bioorg. Med. Chem. Lett., 2015, 25(14), 2753-2757. doi: 10.1016/j.bmcl.2015.05.033 PMID: 26028159
  15. Altıntop, M.D.; Özdemir, A.; Turan-Zitouni, G.; Ilgın, S.; Atlı Ö.; Demirel, R.; Kaplancıklı Z.A. A novel series of thiazolyl–pyrazoline derivatives: Synthesis and evaluation of antifungal activity, cytotoxicity and genotoxicity. Eur. J. Med. Chem., 2015, 92, 342-352. doi: 10.1016/j.ejmech.2014.12.055 PMID: 25576739
  16. Kim, J.; Hong, S.; Hong, S. Discovery of new aminopyrimidine-based phosphoinositide 3-kinase beta (PI3Kβ) inhibitors with selectivity over PI3Kα. Bioorg. Med. Chem. Lett., 2011, 21(23), 6977-6981. doi: 10.1016/j.bmcl.2011.09.118 PMID: 22030027
  17. Giordanetto, F.; Wållberg, A.; Ghosal, S.; Iliefski, T.; Cassel, J.; Yuan, Z.Q.; von Wachenfeldt, H.; Andersen, S.M.; Inghardt, T.; Tunek, A.; Nylander, S. Discovery of phosphoinositide 3-kinases (PI3K) p110β isoform inhibitor 4-2-hydroxyethyl(1-naphthylmethyl)amino-6-(2S)-2-methylmorpholin-4-yl-1H-pyrimidin-2-one, an effective antithrombotic agent without associated bleeding and insulin resistance. Bioorg. Med. Chem. Lett., 2012, 22(21), 6671-6676. doi: 10.1016/j.bmcl.2012.08.102 PMID: 23010262
  18. Ciraolo, E.; Morello, F.; Hirsch, E. Present and future of PI3K pathway inhibition in cancer: perspectives and limitations. Curr. Med. Chem., 2011, 18(18), 2674-2685. doi: 10.2174/092986711796011193 PMID: 21649577
  19. Che, H.; Guo, H.; Si, X.; You, Q.; Lou, W. PP121, a dual inhibitor of tyrosine and phosphoinositide kinases, inhibits anaplastic thyroid carcinoma cell proliferation and migration. Tumour Biol., 2014, 35(9), 8659-8664. doi: 10.1007/s13277-014-2118-3 PMID: 24867098
  20. Herko, A.; Mavis, C.; Czuczman, M. S.; Hernandez, F. AMG 319, a novel inhibitor of phosphoinositide-3 kinase delta (PI3Kd), demonstrates activity in lymphoma pre-clinical models. Am. Soc. Hematol., 2012, 3718-3718. doi: 10.1182/blood.V120.21.3718.3718
  21. Gaonkar, S.L.; Vignesh, U.N. Synthesis and pharmacological properties of chalcones: A review. Res. Chem. Intermed., 2017, 43(11), 6043-6077. doi: 10.1007/s11164-017-2977-5
  22. Joshi, V.D.; Kshirsagar, M.D.; Sarita, S. Synthesis and antimicrobial activities of various pyrazolines from chalcones. Int. J. Chemtech Res., 2012, 4, 971-975.
  23. Van Den Driessche, G.; Fourches, D. Adverse drug reactions triggered by the common HLA-B*57:01 variant: a molecular docking study. J. Cheminform., 2017, 9(1), 13. doi: 10.1186/s13321-017-0202-6 PMID: 28303164
  24. Madhavi Sastry, G.; Adzhigirey, M.; Day, T.; Annabhimoju, R.; Sherman, W. Protein and ligand preparation: Parameters, protocols, and influence on virtual screening enrichments. J. Comput. Aided Mol. Des., 2013, 27(3), 221-234. doi: 10.1007/s10822-013-9644-8 PMID: 23579614
  25. Kumar, S.; Singh, J.; Narasimhan, B.; Shah, S.A.A.; Lim, S.M.; Ramasamy, K.; Mani, V. Reverse pharmacophore mapping and molecular docking studies for discovery of GTPase HRas as promising drug target for bis-pyrimidine derivatives. Chem. Cent. J., 2018, 12(1), 106. doi: 10.1186/s13065-018-0475-5 PMID: 30345469
  26. Sharma, V.; Sharma, P.C.; Kumar, V. In silico molecular docking analysis of natural pyridoacridines as anticancer agents. Adv Chem, 2016, 2016, 5409387. doi: 10.1155/2016/5409387
  27. Deep, A.; Singh, J.; Kumar, M.; Mansuri, R.; Sahoo, G.C. Inhibitor designing, virtual screening, and docking studies for methyltransferase: A potential target against dengue virus. J. Pharm. Bioallied Sci., 2016, 8(3), 188-194. doi: 10.4103/0975-7406.171682 PMID: 27413346
  28. Friesner, R.A.; Murphy, R.B.; Repasky, M.P.; Frye, L.L.; Greenwood, J.R.; Halgren, T.A.; Sanschagrin, P.C.; Mainz, D.T. Extra precision glide: docking and scoring incorporating a model of hydrophobic enclosure for protein-ligand complexes. J. Med. Chem., 2006, 49(21), 6177-6196. doi: 10.1021/jm051256o PMID: 17034125
  29. Lenselink, E.B.; Louvel, J.; Forti, A.F.; van Veldhoven, J.P.D.; de Vries, H.; Mulder-Krieger, T.; McRobb, F.M.; Negri, A.; Goose, J.; Abel, R.; van Vlijmen, H.W.T.; Wang, L.; Harder, E.; Sherman, W.; IJzerman, A.P.; Beuming, T. Predicting binding affinities for GPCR ligands using free-energy perturbation. ACS Omega, 2016, 1(2), 293-304. doi: 10.1021/acsomega.6b00086 PMID: 30023478
  30. Kalra, S.; Joshi, G.; Munshi, A.; Kumar, R. Structural insights of cyclin dependent kinases: Implications in design of selective inhibitors. Eur. J. Med. Chem., 2017, 142, 424-458. doi: 10.1016/j.ejmech.2017.08.071 PMID: 28911822
  31. Nandhakumar, R.; Suresh, T.; Jude, A.L.C. Rajesh kannan, V.; Mohan, P.S. Synthesis, antimicrobial activities and cytogenetic studies of newer diazepino quinoline derivatives via Vilsmeier–Haack reaction. Eur. J. Med. Chem., 2007, 42(8), 1128-1136. doi: 10.1016/j.ejmech.2007.01.004 PMID: 17331623
  32. Hamama, W.S.; Ibrahim, M.E.; Gooda, A.A.; Zoorob, H.H. Recent advances in the chemistry of 2-chloroquinoline-3-carbaldehyde and related analogs. RSC Advances, 2018, 8(16), 8484-8515. doi: 10.1039/C7RA11537G PMID: 35539824
  33. Dhakshinamoorthy, A.; Alvaro, M.; Garcia, H. Claisen–Schmidt condensation catalyzed by metal-organic frameworks. Adv. Synth. Catal., 2010, 352(4), 711-717. doi: 10.1002/adsc.200900747
  34. Guo, S.; Wang, J.; Guo, D.; Zhang, X.; Fan, X. Synthesis of 3,5-disubstituted pyrazoles via cyclocondensation of 1,2-allenic ketones with hydrazines: Application to the synthesis of 5-(5-methyl-pyrazol-3-yl)-2′-deoxycytidine. RSC Advances, 2012, 2(9), 3772-3777. doi: 10.1039/c2ra20274c
  35. Johnson, M.; Younglove, B.; Lee, L.; LeBlanc, R.; Holt, H., Jr; Hills, P.; Mackay, H.; Brown, T.; Mooberry, S.L.; Lee, M. Design, synthesis, and biological testing of pyrazoline derivatives of combretastatin-A4. Bioorg. Med. Chem. Lett., 2007, 17(21), 5897-5901. doi: 10.1016/j.bmcl.2007.07.105 PMID: 17827004
  36. Havrylyuk, D.; Zimenkovsky, B.; Vasylenko, O.; Zaprutko, L.; Gzella, A.; Lesyk, R. Synthesis of novel thiazolone-based compounds containing pyrazoline moiety and evaluation of their anticancer activity. Eur. J. Med. Chem., 2009, 44(4), 1396-1404. doi: 10.1016/j.ejmech.2008.09.032 PMID: 19000643
  37. Roecker, A.J.; Coleman, P.J.; Mercer, S.P.; Schreier, J.D.; Buser, C.A.; Walsh, E.S.; Hamilton, K.; Lobell, R.B.; Tao, W.; Diehl, R.E.; South, V.J.; Davide, J.P.; Kohl, N.E.; Yan, Y.; Kuo, L.C.; Li, C.; Fernandez-Metzler, C.; Mahan, E.A.; Prueksaritanont, T.; Hartman, G.D. Kinesin spindle protein (KSP) inhibitors. Part 8: Design and synthesis of 1,4-diaryl-4,5-dihydropyrazoles as potent inhibitors of the mitotic kinesin KSP. Bioorg. Med. Chem. Lett., 2007, 17(20), 5677-5682. doi: 10.1016/j.bmcl.2007.07.074 PMID: 17766111

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2024 Bentham Science Publishers